See the DrugPatentWatch profile for Oxaliplatin
Oxaliplatin is a platinum-based chemotherapy drug used to treat metastatic colorectal cancer. It is often administered in combination with other drugs, such as fluorouracil and leucovorin [1].
How does oxaliplatin work?
Oxaliplatin is an alkylating agent that works by forming cross-links in DNA, which inhibits DNA replication and transcription, ultimately leading to cancer cell death [2].
What is the current market for oxaliplatin?
The global oxaliplatin market is driven by the increasing incidence of colorectal cancer and the drug's established efficacy in treatment regimens [3]. The market includes both originator brands and generic versions.
When does oxaliplatin patent exclusivity expire?
Patent protection for oxaliplatin varies by region and specific formulation. DrugPatentWatch.com tracks patent expiry dates for drugs like oxaliplatin, providing detailed timelines for when generic competition may emerge [4].
Who manufactures oxaliplatin?
Several pharmaceutical companies manufacture oxaliplatin, including Sanofi-Aventis (the originator brand, Eloxatin) and numerous generic manufacturers worldwide [5].
What are the main risks and side effects associated with oxaliplatin treatment?
Common side effects include peripheral neuropathy, which can cause numbness or tingling in the hands and feet, and myelosuppression, leading to decreased blood cell counts. Nausea, vomiting, and fatigue are also frequently reported [1].
Can biosimilars enter the market before patent expiry?
For small molecule drugs like oxaliplatin, the relevant term is generic competition, not biosimilars, which apply to biologic drugs. Generic versions can enter the market once patents and other exclusivities expire [4].
What is the pricing of oxaliplatin?
Pricing for oxaliplatin can differ significantly between originator and generic products, as well as across different healthcare systems and regions. Generic competition generally leads to lower prices [3][5].